Medtronic’s most advanced hybrid closed-loop system, the MiniMed 780G, has been approved by the FDA. The Medtronic 780G system features SmartGuard technology that automatically adjusts your insulin pump’s output based on CGM readings.
The FDA on April 21 approved the MiniMed 780G, paving the way for Medtronic to distribute its latest insulin pump in the United States. As a hybrid closed-loop system, the MiniMed 780G can connect to the Guardian Connect continuous glucose monitor (CGM) and use its readings to adjust insulin dosing.
The MiniMed 780G was submitted for FDA approval in 2021 but faced a delay in 2022 due to quality control issues at Medtronic’s manufacturing facility. The 780G has been approved in Canada since November 2022 and was previously approved in Europe in 2020.
"Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes and now for the first time, the MiniMed 780G system addresses this unmet need with automatic, real-time insulin corrections," said Que Dallara, president of Medtronic Diabetes, in a statement. "A lot can happen to blood sugars in the span of an hour or even just a few minutes, so we've designed our system for real life – the algorithm adapts to the user and helps compensate for everyday challenges that are quite common around mealtimes."